Elevation Oncology LLC

ELEV · NASDAQ

Price unavailable right now.

No price history for this range.

ELEV analyst rating

This isn't available right now. Refresh to try again.

The case for and against

Updated Jul 31, 2025

Bull case

Elevation Oncology Inc is poised for a favorable outlook due to the anticipated data catalysts surrounding its product candidate, EO-3021, which include additional monotherapy results in 2Q25 and first-in-human combination data expected in late 2025 and early 2026. The innovative combination of EO-3021 with GSK's dostarlimab and Lilly's ramucirumab positions the candidate as a potential leader in treating various solid tumors, especially given its promising efficacy and safety profile. Furthermore, the company's current negative enterprise value of -$32 million indicates an attractive investment opportunity, especially as it prepares to access additional capital amid increasing confidence in its therapeutic advancements.

Bear case

Elevation Oncology faces significant challenges that contribute to a negative outlook on its stock. The company's inability to defend its product portfolio and secure access to capital could halt critical business functions and prolong its path to profitability, thereby affecting shareholder confidence. Additionally, the adverse reaction to initial Phase 1 data for EO-3021, limited revenues reported in Q4 2024, and the inherent risks of clinical trial failures raise concerns about the company's long-term viability and market potential.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.